SEMAX

What is Semax?

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro and is structurally related to the N-terminal fragment of adrenocorticotropic hormone, ACTH(4–10). It has been investigated extensively in experimental research involving the central nervous system and neurobiological signaling.

Research has examined Semax in relation to brain-derived neurotrophic factor (BDNF), TrkB signaling, neurotrophic mechanisms, learning and memory models, inflammatory signaling, and responses to experimental cerebral ischemia. For example, experimental work in rats reported changes in BDNF and TrkB expression following Semax exposure, while other studies have investigated its effects on gene-expression patterns associated with inflammatory and neurotransmitter pathways.

Semax has also been investigated in biochemical research involving peptide interactions, including experimental work examining its interaction with copper ions and amyloid-beta aggregation models.

LP Peptides supplies Semax as a research material for qualified laboratory applications, with applicable product identification and batch documentation.

Research Applications

Semax may be investigated in research involving:

• Neurotrophic signaling
• BDNF-related pathways
• TrkB signaling research
• Neuroprotective mechanisms
• Cognitive and memory research models
• Central nervous system research
• Neuroinflammatory pathways
• Gene-expression studies
• Cerebral ischemia research models
• Peptide pharmacology
• Neurosignaling
• Protein and receptor interactions
• Experimental neurobiology

Experimental studies have specifically examined relationships between Semax and BDNF-related signaling, as well as changes in inflammatory and neurotransmitter-associated gene expression.

Research Context

Semax has been studied as a regulatory peptide in neurobiological and central nervous system research. Its molecular structure is based on an ACTH(4–10)-related sequence, while its biological research profile has focused on mechanisms beyond classical ACTH hormonal activity.

Preclinical research has investigated Semax in models involving learning and memory, neurotrophic signaling, cerebral ischemia, and inflammatory responses. Studies have reported changes in BDNF levels and gene-expression patterns following experimental exposure, although the precise molecular mechanisms underlying these observations remain an area of research.

Research findings should be evaluated according to the experimental model, methodology, species, formulation, and study conditions. Preclinical findings should not automatically be interpreted as evidence of clinical efficacy.

Commonly Compared Research Products

Each compound should be evaluated independently according to the defined research objective, experimental model, and applicable laboratory controls.

Laboratory Handling

Semax should be handled according to the current LP Peptides product documentation, lot-specific information, and applicable laboratory SOP.

Qualified research personnel should:

• Confirm product identity and batch information.
• Review the current Certificate of Analysis (COA).
• Verify the product specification before experimental use.
• Maintain appropriate laboratory inventory records.
• Follow established peptide-handling procedures.
• Minimize unnecessary exposure to unsuitable environmental conditions.
• Document relevant experimental parameters.
• Use appropriate laboratory controls for experimental studies.

Storage Guidelines

Research Use Disclaimer

Semax supplied by LP Peptides is intended strictly for qualified laboratory research purposes.

This product:

• Is not intended for human use.
• Is not intended for veterinary use.
• Is not intended for consumption.
• Is not supplied as a treatment or medical product.
• Should only be handled by appropriately qualified research personnel.
• Should not be represented as an approved therapeutic product.

Information provided on this page is for scientific reference and product identification and does not constitute medical advice, dosing guidance, or a therapeutic claim.

COA & Quality Assurance

Researchers should review the applicable lot-specific documentation before using Semax in an experimental setting.

Frequently Asked Questions